

Remarks

Reconsideration of this Application is respectfully requested.

The above amendments do not add new matter. The amendments correct a formal matter without changing the scope of the claims. Specifically, the amendments are in response to the Office Communication, dated October 22, 2002, requesting the insertion of SEQ ID numbers for reference peptides found in the tables located on pages 33-179 of the specification. Applicants point out that all of the peptide sequences listed in Tables 1-3 and 5-6 are sequences contained within the full-length C35 polypeptide sequence of SEQ ID NO: 2 at the positions noted. As such, they do not require their own SEQ ID NOS. Paragraph 87 has been amended to further clarify this. Table 4, in addition to listing peptide sequences contained in SEQ ID NO: 2, also contains "modified" C35 peptide sequences containing amino acid substitutions. The modified sequences correspond to SEQ ID NOS: 85-147. Table 4 has been amended to specifically associate the SEQ ID NOS with the corresponding sequences. These changes are believed to introduce no new matter, and their entry is respectfully requested.

Conclusion


Applicants believe that a full and complete reply has been made to the outstanding Office Communication. If the Examiner believes, for any reason, that

personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of this Amendment and Reply is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, appearing to read "Timothy J. Shea, Jr.", written in a cursive style.

Timothy J. Shea, Jr.
Attorney for Applicant
Registration No. 41,306

Date: 11/22/02

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

Version with markings to show changes made

--A number of computer algorithms have been described for identification of peptides in a larger protein that may satisfy the requirements of peptide binding motifs for specific MHC class I or MHC class II molecules. Because of the extensive polymorphism of MHC molecules, different peptides will often bind to different MHC molecules. Tables 1-3 list C35 peptides predicted to be MHC binding peptides using three different algorithms. Specifically, Tables 1 and 5 list C35 HLA Class I and II epitopes predicted using the rules found at the SYFPEITHI website

([wysiwyg://35/http://134.2.96.221/scripts/hlaserver.dll/EpPredict.htm](http://35/http://134.2.96.221/scripts/hlaserver.dll/EpPredict.htm)) and are based on the book "MHC Ligands and Peptide Motifs" by Rammensee, H.G., Bachmann, J. and Stevanovic, S. (Chapman & Hall, New York 1997). Table 2 lists predicted MHC binding peptides derived from the C35 sequence using the NIH BIMAS program available on the web (http://bimas.dcrf.nih.gov/cgi-bin/molbio/ken_parker_comboform).

Finally, Tables 3 and 6 list predicted C35 peptides identified by the Tepitope program, a program for prediction of peptides that may bind to multiple different MHC class II molecules. Using Tepitope, four C35 peptides were identified as likely candidates for binding to a variety of HLA class II molecules. These peptides are, in general, longer than those binding to HLA class I and more degenerate in terms of binding to multiple HLA class II molecules. Unless expressly noted otherwise, all peptide sequences listed in Tables 1-6 refer to C35 peptide sequences appearing in SEQ ID NO:2 at the amino acid positions noted.--

TABLE 4

Modifications that Enhance HLA Class I Binding

(Unless otherwise indicated, examples apply to peptides of 9 amino acids; for 10-mers the amino acid at position 5 is disregarded and the resultant 9-mer is evaluated (http://bimas.dcrt.nih.gov/cgi-bin/molbio/hla_coefficient_viewing_page). The modifications listed below are provided by way of example based on current data in existing databases and are not intended in any way to be an inclusive list of all potential alterations of peptides binding all potential HLA molecules, both known and unknown to date.)

HLA A*0101

Any altered peptide that has S or T at position 2

Any altered peptide that has D or E at position 3

Any altered peptide that has P at position 4

Any altered peptide that has A, F, I, L, M, P, V, or Y at position 7

Any altered peptide that has F, K, R, or Y at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: D, E, F, G, H, K, M, N, P, Q, R, W, Y

P3: E, K, R, W

P4: K, R

P7: D, E, G, R

P9: D, E, P

HLA A*0201

Any altered peptide that has F, I, K, L, M, V, W, or Y at position 1

Any altered peptide that has I, L, M, Q, or V at anchor position 2

Any altered peptide that has F, L, M, W, or Y at position 3

Any altered peptide that has D or E at position 4

Any altered peptide that has F at position 5

Any altered peptide that has F, I, L, M, V, W or Y at auxiliary anchor position 6

Any altered peptide that has F, or W at position 7

Any altered peptide that has F, W, or Y at position 8

Any altered peptide that has I, L, T or V at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: D, E, H, P
P2: C, F, H, K, N, P, R, S, W, Y
P3: D, E, K, R
P7: D, E, G, R
P8: I, V
P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y

HLA-A*0205

Any altered peptide that has F, I, K, L, M, V, W, or Y at position 1

Any altered peptide that has E, I, L, M, Q, or V at anchor position 2

Any altered peptide that has F, L, M, W, or Y at position 3

Any altered peptide that has D or E at position 4

Any altered peptide that has F, Y at position 5

Any altered peptide that has F, I, L, M, V, W or Y at auxiliary anchor position 6

Any altered peptide that has F, or W at position 7

Any altered peptide that has F, W, or Y at position 8

Any altered peptide that has I, L, T or V at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: D, E, P
P2: C, D, F, G, H, K, N, P, R, S, W, Y
P3: D, E, K, R
P7: D, E, R
P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y

HLA-A*03

Any altered peptide that has G or K at position 1

Any altered peptide that has I, L, M, Q, T or V at anchor position 2

Any altered peptide that has F, I, L, M, V, W, or Y at position 3

Any altered peptide that has E, G or P at position 4

Any altered peptide that has F, I, P, V, W, Y at position 5

Any altered peptide that has F, I, L, M, or V at position 6

Any altered peptide that has F, I, L, M, W, or Y at position 7

Any altered peptide that has F, I, K, L, Q or Y at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: D, E, P

P2: D, E, F, G, H, K, N, R, S, W, Y

P7: G, K, R

P9: D, E, G, H, N, P, Q, S, T

HLA-A*1101

Any altered peptide that has G, K or R at position 1

Any altered peptide that has I, L, M, Q, T, V, Y at anchor position 2

Any altered peptide that has F, I, L, M, V, W, Y at position 3

Any altered peptide that has F, I, L, M, W or Y at position 7

Any altered peptide that has K or R at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: D, E, P

P2: D, E, G, H, K, N, R, S, W

P7: K, R

P9: C, D, E, G, N, P, Q, S, T

HLA-A24

Any altered peptide that has K or R at position 1

Any altered peptide that has F or Y at anchor position 2

Any altered peptide that has E, I, L, M, N, P, Q, or V at position 3

Any altered peptide that has D, E, or P at position 4

Any altered peptide that has I, L, or V at position 5

Any altered peptide that has F at position 6

Any altered peptide that has N or Q at position 7

Any altered peptide that has E or K at position 8

Any altered peptide that has F, I, L, or M at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: D, E, H, K, R

P9: D, E, G, H, K, P, Q, R

HLA-A*3101

Any altered peptide that has K or R at position 1

Any altered peptide that has F, I, L, M, Q, T, V, or Y at anchor position 2

Any altered peptide that has F, I, L, M, V W, or Y at position 3

Any altered peptide that has F, I, L, M, or V at position 6

Any altered peptide that has F, I, L, M, W, or Y at position 7

Any altered peptide that has K or R at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: D, E, P

P2: D, E, G, H, K, N, R, S

P7: K, R

P9: C, G, N, P, Q, S, T

HLA-A*3302

Any altered peptide that has D or E at position 1

Any altered peptide that has I, L, M, S, V or Y at anchor position 2

Any altered peptide that has R at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: K, P, R

P2: D, E, K, R

P9: D, E, F, G, N, P, W, Y

HLA-B7

Any altered peptide that has A at position 1

Any altered peptide that has A, P or V at anchor position 2

Any altered peptide that has M or R at position 3

Any altered peptide that has P at position 5

Any altered peptide that has R at position 6

Any altered peptide that has I, L, M or V at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P
P2: D, E, F, H, K, R, W, Y
P3: D, E
P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y

HLA-B8

Any altered peptide that has D or E at position 1

Any altered peptide that has A, C, L, or P at anchor position 2

Any altered peptide that has K or R at position 3

Any altered peptide that has D or E at position 4

Any altered peptide that has K or R at position 5

Any altered peptide that has I, L, M, or V at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: K, P, R
P2: D, E, F, G, H, K, Q, R, W, or Y
P3: D, E
P5: D, E
P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y

HLA-B8 (8-mer peptides)

Any altered peptide that has D or E at position 1

Any altered peptide that has A, C, L, or P at anchor position 2

Any altered peptide that has K or R at position 3

Any altered peptide that has D or E at position 4

Any altered peptide that has K or R at position 5

Any altered peptide that has I, L, M, or V at anchor position 8

Any altered peptide where deleterious residues at the following positions are replaced:

P1: K, P, R
P2: D, E, F, G, H, K, Q, R, W, or Y
P3: D, E
P5: D, E
P8: D, E, F, G, H, K, N, P, Q, R, S, W, Y

HLA-B14

Any altered peptide that has D or E at position 1

Any altered peptide that has K or R at anchor position 2

Any altered peptide that has F, I, L, M, P, V, W, Y at position 3

Any altered peptide that has H or R at position 5

Any altered peptide that has I, L, M, R, or V at position 6

Any altered peptide that has T at position 7

Any altered peptide that has I, L, M, or V at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: D, E, F, W, or Y

P3: E, R

P5: E, W, Y

P9: D, E, G, H, K, N, P, Q, R

HLA-B*2702

Any altered peptide that has K or R at position 1

Any altered peptide that has E, L, M, N, Q or R at anchor position 2

Any altered peptide that has F, W, or Y at position 3

Any altered peptide that has F, I, L, W or Y at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: D, E, P

P2: D, F, G, H, K, W, or Y

P7: K

P9: D, E, G, K, N, P, Q, R, S

HLA-B27*05 (8-mer peptides)

Any altered peptide that has K or R at position 1

Any altered peptide that has E, L, M, N, Q or R at anchor position 2

Any altered peptide that has F, W, or Y at position 3

Any altered peptide that has F, I, K, L, M, R, V or Y at anchor position 8

Any altered peptide where deleterious residues at the following positions are replaced:

P1: D, E, P

P2: D, F, G, H, K, W, or Y

P7: K

P9: D, E, G, K, N, P, Q, R, S

HLA-B*3501 (8-mer peptides)

Any altered peptide that has K or R at position 1

Any altered peptide that has A, P, or S at anchor position 2

Any altered peptide that has K or R at position 3

Any altered peptide that has D or E at position 4

Any altered peptide that has D or E at position 5

Any altered peptide that has F, I, L, M, V, W or Y at anchor position 8

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: D, E, F, H, K, R, W, Y

P3: D, E

P8: D, E, F, G, H, K, P, Q, R

HLA-B*3701

Any altered peptide that has D or E at anchor position 2

Any altered peptide that has I or V at position 5

Any altered peptide that has F, L, or M at position 8

Any altered peptide that has F, I, L, M, V or Y at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P9: D, E, G, H, K, P, Q, R

HLA-B*3801

Any altered peptide that has F, H, P, W or Y at anchor position 2

Any altered peptide that has D or E at position 3

Any altered peptide that has D, E, or G at position 4

Any altered peptide that has A, I, L, M, or V at position 5

Any altered peptide that has K or Y at position 8

Any altered peptide that has F, I, L, M, or V at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: D, E, K, R

P3: K, R

P9: D, E, G, H, K, P, Q, R

HLA-B*3901 (8-mer peptides)

Any altered peptide that has H or R at anchor position 2

Any altered peptide that has D, E, F, I, L, M, V, W, or W at position 3

Any altered peptide that has D or E at position 4

Any altered peptide that has I, L, M, or V at position 6

Any altered peptide that has I, L, M or V at anchor position 8

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: D, E

P3: K, R

P6: D, E, K, R

P8: D, E, G, H, K, P, Q, R

HLA-B*3902

Any altered peptide that has K or Q at anchor position 2

Any altered peptide that has F, I, L, M, V, W, or Y at position 5

Any altered peptide that has F, L, or M at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: D, E

P3: K, R

P9: D, E, G, H, K, P, Q, R

HLA-B40

Any altered peptide that has A or G at position 1

Any altered peptide that has D or E at anchor position 2

Any altered peptide that has A, F, I, L, M, V, W, or Y at position 3

Any altered peptide that has P at position 4

Any altered peptide that has P at position 5

Any altered peptide that has A, L, M, or W at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: F, H, I, K, L, M, Q, R, V, W, or Y

P3: D, E, K, R

P9: D, E, G, H, K, N, P, Q, R

HLA-B44*03

Any altered peptide that has A, D, or S at position 1

Any altered peptide that has D or E at anchor position 2

Any altered peptide that has A, I, L, M, or V at position 3

Any altered peptide that has F, I, or P at position 4

Any altered peptide that has A, K, or V at position 5

Any altered peptide that has A, L, T, or V at position 6

Any altered peptide that has F, K, or T at position 7

Any altered peptide that has K at position 8

Any altered peptide that has F, W or Y at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: F, H, I, K, L, M, Q, R, V, W, Y

P9: D, E, G, H, K, N, P, Q, R

HLA-B*5101 (8-mer peptides)

Any altered peptide that has D, E, F, I, L, M, V, or Y at position 1

Any altered peptide that has A, G or P at anchor position 2

Any altered peptide that has F, W or Y at position 3

Any altered peptide that has D, E, G, I, K, or V at position 4

Any altered peptide that has A, G, I, S, T, or V at position 5

Any altered peptide that has I, K, L, N, or Q at position 6

Any altered peptide that has D, K, Q, or R at position 7

Any altered peptide that has I, L, M, or V at anchor position 8

Any altered peptide where deleterious residues at the following positions are replaced:

P1: K, P, R

P2: D, E, H, K

P8: D, E, F, G, H, K, N, P, Q, R, S, W, Y

HLA-B*5102

Any altered peptide that has F or Y at position 1

Any altered peptide that has A, G, or P at anchor position 2

Any altered peptide that has F, I, L, V, W, or Y at position 3

Any altered peptide that has E, G, H, K, L, N, Q, R, or T at position 4

Any altered peptide that has G, N, Q, T, or V at position 5

Any altered peptide that has I, N, Q, or T at position 6

Any altered peptide that has E, K, Q, or R at position 7

Any altered peptide that has K, R, T, or Y at position 8

Any altered peptide that has I, L, M, or V at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: D, E, H, K, R

P3: D, E, K, R

P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y

HLA-B*5102 (8-mer peptides)

Any altered peptide that has F or Y at position 1

Any altered peptide that has A, G, or P at anchor position 2

Any altered peptide that has F, I, L, V, W, or Y at position 3

Any altered peptide that has E, G, H, K, L, V, W, or Y at position 4

Any altered peptide that has G, N, Q, T, V at position 5

Any altered peptide that has I, N, or Q at position 6

Any altered peptide that has Q, or R at position 7

Any altered peptide that has I, L, M, or V at position 8

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: D, E, H, K, R

P3: D, E, K, R

P8: D, E, F, G, H, K, N, P, Q, R, S, W, Y

HLA-B*5103

Any altered peptide that has D, T, or V at position 1

Any altered peptide that has A, G, or P at anchor position 2

Any altered peptide that has D, F, L, or Y at position 3

Any altered peptide that has E, G, L, N, Q, R, T, or V at position 4

Any altered peptide that has A, G, M, N, Q, R, K or V at position 5

Any altered peptide that has I, K, or T at position 6

Any altered peptide that has M or V at position 7

Any altered peptide that has I, L, M, or V at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: D, E, H, K, R

P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y

HLA-B*5201 (8-mer peptides)

Any altered peptide that has I, L, M, or V at position 1

Any altered peptide that has G, P, or Q at anchor position 2

Any altered peptide that has D, F, I, L, P, W, or Y at position 3

Any altered peptide that has A, E, I, K, L, P, or V at position 4

Any altered peptide that has A, F, G, I, L, M, T or V at position 5

Any altered peptide that has K, L, N, S or T at position 6

Any altered peptide that has E, K, Q, or Y at position 7

Any altered peptide that has F, I, L, M, or V at anchor position 8

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: H, K, R

P3: R

P8: D, E, G, H, K, N, P, Q, R, S

HLA-B*5801

Any altered peptide that has I, K, or R at position 1

Any altered peptide that has A, S, or T at anchor position 2

Any altered peptide that has D at position 3

Any altered peptide that has E, K, or P at position 4

Any altered peptide that has F, I, L, M, or V at position 5

Any altered peptide that has F, I, L, or V at position 6

Any altered peptide that has L, M, N, or Y at position 7

Any altered peptide that has K, N, R, or T at position 8

Any altered peptide that has F, W, or Y at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: D, E, P

P2: D, E, F, H, I, K, L, M, N, Q, R, V, W, Y

P9: D, E, G, H, K, N, P, Q, R, S

HLA-B*60

Any altered peptide that has D or E at anchor position 2

Any altered peptide that has A, I, L, M, S, or V at position 3

Any altered peptide that has L, I, or V at position 5

Any altered peptide that has I, L, M, V, or Y at position 7

Any altered peptide that has K, Q, or R at position 8

Any altered peptide that has I, L, M, or V at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: F, H, I, K, L, M, Q, R, V, W, Y

P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y

HLA-B*61

Any altered peptide that has G or R at position 1

Any altered peptide that has D or E at anchor position 2

Any altered peptide that has A, F, I, L, M, T, V, W, or Y at position 3

Any altered peptide that has I at position 6

Any altered peptide that has Y at position 7

Any altered peptide that has A, I, L, M, or V at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: F, H, I, K, L, M, Q, R, V, W, Y

P9: D, E, F, G, H, K, N, P, Q, R, S, W, Y

HLA-B*61 (8-mer peptides)

Any altered peptide that has G or R at position 1

Any altered peptide that has D or E at anchor position 2

Any altered peptide that has A, F, I, L, M, T, V, W, or Y at position 3

Any altered peptide that has I at position 6

Any altered peptide that has Y at position 7

Any altered peptide that has A, I, L, M, or V at anchor position 8

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: F, H, I, K, L, M, Q, R, V, W, Y

P8: D, E, F, G, H, K, N, P, Q, R, S, W, Y

HLA-B*62

Any altered peptide that has I at position 1

Any altered peptide that has I, L, Q at anchor position 2

Any altered peptide that has G, K, R at position 3

Any altered peptide that has D, E, G, or P at position 4

Any altered peptide that has F, G, I, L, or V at position 5

Any altered peptide that has I, L, T, V at position 6

Any altered peptide that has T, V, or Y at position 7

Any altered peptide that has F, W, Y at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: D, E, F, H, K, N, R, S, W, Y

P3: D, E

P6: D, E, K, R

P9: D, E, G, H, K, N, P, Q, R, S

HLA-Cw0301

Any altered peptide that has A or R at anchor position 2

Any altered peptide that has F, I, L, M, V, or Y at position 3

Any altered peptide that has E, P, or R at position 4

Any altered peptide that has N at position 5

Any altered peptide that has F, M, or Y at position 6

Any altered peptide that has K, M, R, or S at position 7

Any altered peptide that has T at position 8

Any altered peptide that has F, I, L, M at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P3: D, K, R

P6: D, E, K, R

P9: D, E, G, H, K, N, P, Q, R, S,

HLA-Cw0401

Any altered peptide that has F, P, W, or Y at anchor position 2

Any altered peptide that has D, or H at position 3

Any altered peptide that has D or E at position 4

Any altered peptide that has A, H, M, R, or T at position 5

Any altered peptide that has I, L, M, or V at position 6

Any altered peptide that has A at position 7

Any altered peptide that has H, K, or S at position 8

Examples of predicted human Class I MHC binding peptides – **continued**

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

Any altered peptide that has F, I, L, M, V or Y at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P2: D, E, H, K, R

P9: D, E, G, H, K, N, P, Q, R, S

HLA-Cw0602

Any altered peptide that has F, I, K, or Y at position 1

Any altered peptide that has A, P, Q, or R at anchor position 2

Any altered peptide that has F, I, K, L, or M at position 5

Any altered peptide that has I, L, or V at position 6

Any altered peptide that has K, N, Q, or R at position 7

Any altered peptide that has I, L, M, V, or Y at anchor position 9

Any altered peptide where deleterious residues at the following positions are replaced:

P1: P

P9: D, E, G, H, K, N, P, Q, R, S

Examples of predicted human Class I MHC binding peptides from the C35 aa sequence and how they might be changed to improve binding:

HLA-A*0101

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
1	77	KLENGGRPY	225.000	
2	16	EVEPGSGVR	90.000	
3	29	YCEPCGFEA	45.000	
4	39	YLELASAVK	36.000	
5	2	SGEPGQTSV	2.250	G is deleterious at P2
example of improved peptide				
		STEPGQTSV	22.50	G replaced with T @ P2
				<u>SEQ ID NO:85</u>

Examples of predicted human Class I MHC binding peptides – continued

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	----------------	-------------	--	------------

example of improved peptide		STEPGQISY	5625.00	V at P9 replaced with Y, P7 enhanced	SEQ ID NO:86
-----------------------------	--	-----------	---------	--------------------------------------	--------------

HLA-A*0101 (10-mer peptides)

1	66	EIEINGQLVF	45.000
2	16	EVEPGSGVRI	18.000
3	29	YCEPCGFEAT	9.000
4	26	VVEYCEPCGF	9.000
5	52	GIEIESRLGG	2.250

example of improved peptide		GTEPSRLGY	1125.000	replace I with T @P2 replace G with Y @P9 P5 enhanced with P	SEQ ID NO:87
-----------------------------	--	-----------	----------	--	--------------

HLA-A*0201 (9-mer peptides)

1	9	SVAPPPEEV	2.982
2	104	KITNSRPPC	2.391
3	105	ITNSRPPCV	1.642
4	25	IVVEYCEPC	1.485
5	65	FEIEINGQL	1.018

example of improved peptide		FLIEINWYL	16619.000		SEQ ID NO:88
-----------------------------	--	-----------	-----------	--	--------------

HLA-A*0201 (10-mer peptides)

1	58	RLGGTGAFEI	60.510	
2	104	KITNSRPPCV	33.472	
3	65	FEIEINGQLV	25.506	
4	83	FPYEKDLIEA	4.502	P is deleterious at P2

example of improved peptide		FLYEKDLIEA	689.606	replace P with L @ P2	SEQ ID NO:89
-----------------------------	--	------------	---------	-----------------------	--------------

Examples of predicted human Class I MHC binding peptides – continued

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)		SEQ ID NO.
------	----------------	-------------	--	--	------------

example of improved peptide		FLYEKDLIEV	9654.485	replace A with V @ P9	<u>SEQ ID NO:90</u>
-----------------------------	--	------------	----------	-----------------------	---------------------

5	33	CGFEATYLEL	3.173		
---	----	------------	-------	--	--

HLA-A*0205

1	65	FEIEINGQL	8.820		
---	----	-----------	-------	--	--

2	25	IVVEYCEPC	3.060		
---	----	-----------	-------	--	--

3	9	SVAPPPEEV	2.000		
---	---	-----------	-------	--	--

4	104	KITNSRPPC	1.500		
---	-----	-----------	-------	--	--

5	81	GGFPYEKDL	1.260	G is deleterious at P2	
---	----	-----------	-------	------------------------	--

example of improved peptide		GVFPYEKDL	50.400	replace G with V @ P2	<u>SEQ ID NO:91</u>
-----------------------------	--	-----------	--------	-----------------------	---------------------

HLA-A*0205 (10-mer peptides)

1	33	CGEFATYLEL	6.300	G is deleterious at P2	
---	----	------------	-------	------------------------	--

example of improved peptide		CVEFATYLEL	11.200	replace G with V @ P2	<u>SEQ ID NO:92</u>
-----------------------------	--	------------	--------	-----------------------	---------------------

2	104	KITNSRPPCV	6.000		
---	-----	------------	-------	--	--

3	65	FEIEINGQLV	2.520		
---	----	------------	-------	--	--

4	53	IEIESRLGGT	1.428		
---	----	------------	-------	--	--

5	83	FPYEKDLIEA	1.350	P is deleterious at P2	
---	----	------------	-------	------------------------	--

example of improved peptide		FVYEKDLIEA	54.000	replace P with V @ P2	<u>SEQ ID NO:93</u>
-----------------------------	--	------------	--------	-----------------------	---------------------

HLA-A24

1	34	GFEATYLEL	33.000		
---	----	-----------	--------	--	--

2	49	QYPGIEIES	11.550		
---	----	-----------	--------	--	--

example of improved peptide		QYPGIEIEL	462.000	enhance P9	<u>SEQ ID NO:94</u>
-----------------------------	--	-----------	---------	------------	---------------------

3	70	NGQLZFSKL	11.088		
---	----	-----------	--------	--	--

Examples of predicted human Class I MHC binding peptides – **continued**

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

4	38	TYLELASAV	10.800	
---	----	-----------	--------	--

5	82	GFPYEKDLI	7.500	
---	----	-----------	-------	--

HLA-A24 (10-mer peptides)

1	64	AFEIEINGQL	42.000	
---	----	------------	--------	--

2	74	VFSKLENGGF	10.000	
---	----	------------	--------	--

3	84	PYEKDLIEAI	9.000	
---	----	------------	-------	--

4	69	INGQLVFSKL	7.392	
---	----	------------	-------	--

example of improved peptide	IYGQLVFSKL	369.6	enhance P2	<u>SEQ ID NO:95</u>
-----------------------------	------------	-------	------------	---------------------

5	28	EYCEPCGFEA	6.600	
---	----	------------	-------	--

HLA-A3

1	77	KLENGGFPY	36.000	
---	----	-----------	--------	--

example of improved peptide	KLENGGFPK	180.000	enhance P9	<u>SEQ ID NO:96</u>
-----------------------------	-----------	---------	------------	---------------------

2	39	YLELASAVK	20.000	
---	----	-----------	--------	--

3	101	TLEKITNSR	6.000	
---	-----	-----------	-------	--

4	61	GTGA FEIEI	0.540	
---	----	------------	-------	--

5	69	IVGQLVFSK	0.360	N is deleterious @ P2
---	----	-----------	-------	-----------------------

example of improved peptide	ILGQLVFSK	180.000	replace N with L @ P2	<u>SEQ ID NO:97</u>
-----------------------------	-----------	---------	-----------------------	---------------------

HLA-A3 (10-mer peptides)

1	68	EINGQLVFSK	8.100	
---	----	------------	-------	--

2	58	RLGGTGAFEI	2.700	
---	----	------------	-------	--

3	41	ELASAVKEQY	1.800	
---	----	------------	-------	--

4	78	LENGGFPYEK	0.810	E is deleterious @ P2
---	----	------------	-------	-----------------------

example of improved peptide	LLNGGFPYEK	270.000	replace E with L @ P2	<u>SEQ ID NO:98</u>
-----------------------------	------------	---------	-----------------------	---------------------

Examples of predicted human Class I MHC binding peptides – c ntinued

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

5	95	RASNGETLEK	0.400	
---	----	------------	-------	--

HLA- A*1101

1	39	YLELASAVK	0.400	
---	----	-----------	-------	--

2	69	INGQLVFSK	0.120	<i>N</i> is deleterious @ P2
---	----	-----------	-------	------------------------------

example of
improved peptide

		IVGQLVFSK	6.000	
--	--	-----------	-------	--

replace N with V @ P2

SEQ ID NO:99

3	16	EVEPGSGVR	0.120	
---	----	-----------	-------	--

4	101	TLEKITNSR	0.080	
---	-----	-----------	-------	--

5	61	GTGAFEIEI	0.060	
---	----	-----------	-------	--

HLA-A*1101 (10-mer peptides)

1	95	RASNGETLEK	1.200	
---	----	------------	-------	--

2	38	TYLELASAVK	0.600	
---	----	------------	-------	--

3	68	EINGGLVFSK	0.360	
---	----	------------	-------	--

4	78	LENGGFPEYK	0.120	<i>E</i> is deleterious @ P2
---	----	------------	-------	------------------------------

example of
improved peptide

		LVNGGFPEYK	4.000	
--	--	------------	-------	--

replace E with V @ P2

SEQ ID NO:100

5	100	ETLEKITNSR	0.090	
---	-----	------------	-------	--

HLA-A*3101

1	101	TLEKITNSR	2.000	
---	-----	-----------	-------	--

2	16	EVEPGSGVR	0.600	
---	----	-----------	-------	--

3	50	YPGIEIESR	0.400	
---	----	-----------	-------	--

4	87	KDLIEAIRR	0.240	<i>D</i> is deleterious @ P2
---	----	-----------	-------	------------------------------

example of
improved peptide

		KILIEAIRR	12.000	
--	--	-----------	--------	--

replace D with I @ P2

SEQ ID NO:101

5	39	YLELASAVK	0.200	
---	----	-----------	-------	--

Examples of predicted human Class I MHC binding peptides – c ntinued

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

HLA-A*3302

1	16	EVEPGSGVR	45.000	
2	101	TLEKITNSR	9.000	
3	50	YPGIEIESR	3.000	
4	66	EIEINGQLV	1.500	
5	56	ESRLGGTGA	1.500	

HLA-A*3302 (10-mer peptides)

1	49	QYPGIEIESR	15.000	
2	100	ETLEKITNSR	9.000	
3	16	EVEPGSGVRI	1.500	
4	28	EYCEPCGFEA	1.500	
5	68	EINGQLVFSK	1.500	

HLA-A68.1

1	16	EVEPGSGVR	900.000	
2	9	SVAPPPEEV	12.000	
3	50	YPGIEIESR	10.000	
example of improved peptide		YVGIEIESR	400.000	
4	96	ASNGETLEK	9.000	
5	101	TLEKITNSR	5.000	

enhance P2

SEQ ID NO:102

HLA-A68.1 (10-mer peptides)

1	100	ETLEKITNSR	300.000	
2	16	EVEPGSGVRI	18.000	
3	68	EINGGLVFSK	9.000	
4	15	EEVEPGSGVR	9.000	

E is deleterious @ P2

Examples of predicted human Class I MHC binding peptides – continued

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)		SEQ ID NO.
------	-------------------	-------------	--	--	------------

example of improved peptide		EVVEPGSGR	1200.00	replace E with V @ P2	<u>SEQ ID NO:103</u>
--------------------------------	--	-----------	---------	-----------------------	----------------------

5	95	RASNGETLEK	3.000		
---	----	------------	-------	--	--

HLA-B14

1	94	RRASNGETL	20.000		
---	----	-----------	--------	--	--

2	57	SRLGGTGAF	5.000		
---	----	-----------	-------	--	--

example of improved peptide		SRLGGTGAL	100.000	enhance P9	<u>SEQ ID NO:104</u>
--------------------------------	--	-----------	---------	------------	----------------------

3	100	ETLEKITNS	3.375		
---	-----	-----------	-------	--	--

4	105	ITNSRPPCV	2.000		
---	-----	-----------	-------	--	--

5	88	DLIEAIRRA	1.350		
---	----	-----------	-------	--	--

HLA-B14 (10-mer peptides)

1	103	EKITNSRPPC	6.750		
---	-----	------------	-------	--	--

example of improved peptide		ERITNSRPPL	900.000	enhance P10	<u>SEQ ID NO:105</u>
--------------------------------	--	------------	---------	-------------	----------------------

2	33	CGFEATYLEL	5.000		
---	----	------------	-------	--	--

3	93	IRRASNGETL	4.000		
---	----	------------	-------	--	--

4	18	EPGSGVRIVV	3.000		
---	----	------------	-------	--	--

5	88	DLIEAIRRAS	2.250		
---	----	------------	-------	--	--

HLA-B40

1	65	FEIEINGQL	80.000		
---	----	-----------	--------	--	--

2	3	GEPGQTSVA	40.000		
---	---	-----------	--------	--	--

3	35	FEATYLELA	40.000		
---	----	-----------	--------	--	--

4	15	EEVEPGSGV	24.000		
---	----	-----------	--------	--	--

example of improved peptide		EEVEPGSGL	120.000	enhance P9	<u>SEQ ID NO:106</u>
--------------------------------	--	-----------	---------	------------	----------------------

5	67	IEINGQLVF	16.000		
---	----	-----------	--------	--	--

Examples of predicted human Class I MHC binding peptides – **continued**

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

HLA-B40 (10-mer peptides)

1	55	IESRLGGTGA	20.000
---	----	------------	--------

2	53	IEIESRLGGT	16.000
---	----	------------	--------

example of
improved peptide

IEIESRLGGL	80.000
------------	--------

enhance P10

SEQ ID NO:107

3	65	FEIEINGQLV	16.000
---	----	------------	--------

4	67	IEINGQLVFS	16.000
---	----	------------	--------

5	99	GETLEKITNS	8.000
---	----	------------	-------

HLA-B60

1	65	FEIEFNGQL	387.200
---	----	-----------	---------

2	17	VEPGSGVRI	17.600
---	----	-----------	--------

example of
improved peptide

VEPGSGVRL	352.000
-----------	---------

enhance P9

SEQ ID NO:108

3	15	EEVEPGSGV	16.000
---	----	-----------	--------

4	47	KEQYPGIEI	16.000
---	----	-----------	--------

5	85	YEKDLIEAI	8.800
---	----	-----------	-------

HLA-B60 (10-mer peptides)

1	65	FEIEINGQLV	16.000
---	----	------------	--------

example of
improved peptide

FEIEINGQLL	320.000
------------	---------

enhance P10

SEQ ID NO:109

2	106	TNSRPPCVIL	16.000
---	-----	------------	--------

3	53	IEIESRLGGT	8.000
---	----	------------	-------

4	33	CGFEATYLEL	8.000
---	----	------------	-------

5	17	VEPGSGVRIV	8.000
---	----	------------	-------

Examples of predicted human Class I MHC binding peptides – **continued**

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

HLA-B61

1	15	EEVEPGSGV	80.000
---	----	-----------	--------

2	35	FEATYLELA	40.000
---	----	-----------	--------

example of
improved peptide

		FEATYLELV	160.000
--	--	-----------	---------

enhance P9

SEQ ID NO:110

3	3	GEPGQTSVA	22.000
---	---	-----------	--------

4	65	FEIEINGQL	16.000
---	----	-----------	--------

5	85	YEKDLIEAI	16.000
---	----	-----------	--------

HLA-B61 (10-mer peptides)

1	65	FEIEINGQLV	80.000
---	----	------------	--------

2	17	VEPGSGVRIV	40.000
---	----	------------	--------

3	55	IESRLGGTGA	20.000
---	----	------------	--------

4	87	KDLIEAIRRA	10.000
---	----	------------	--------

example of
improved peptide

		KELIEAIRRV	160.000
--	--	------------	---------

enhance P2, P10

SEQ ID NO:111

5	53	IEIESRLGGT	8.000
---	----	------------	-------

HLA-B62

1	77	KLENGGFPY	24.000
---	----	-----------	--------

2	21	SGVRIVVEY	4.800
---	----	-----------	-------

3	75	FSKLENGGF	3.000
---	----	-----------	-------

4	31	EPCGFEATY	2.640
---	----	-----------	-------

P is deleterious @ P2

example of
improved peptide

		EQCGFEATY	105.6
--	--	-----------	-------

replace P with Q @ P2

SEQ ID NO:112

5	88	DLIEAIRRA	2.200
---	----	-----------	-------

Examples of predicted human Class I MHC binding peptides – c ntinued

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

HLA-B62 (10-mer peptides)

1	41	ELASAVKEQY	40.000	
2	58	RLGGTGAFEI	9.600	
3	66	EIEINGQLVF	7.920	
4	56	ESRLGGTGAF	6.000	S is deleterious @ P2

example of improved peptide	EQRLGGTGAF	480.000	replace S with Q @ P2	<u>SEQ ID NO:113</u>
-----------------------------	------------	---------	-----------------------	----------------------

5	20	GSGVRIVVEY	4.800	S is deleterious @ P2
---	----	------------	-------	-----------------------

example of improved peptide	GQGVRIIVVEY	384.000	replace S with Q @P2	<u>SEQ ID NO:114</u>
-----------------------------	-------------	---------	----------------------	----------------------

HLA-B7

1	107	NSRPPCVIL	60.000	
example of improved peptide	NPRPPCVIL	1200.000	enhance P2	<u>SEQ ID NO:115</u>

2	45	AVKEQYPGI	6.000	
3	22	GVRIVVEYC	5.000	
4	70	NGQLVFSKL	4.000	
5	81	GGFPYEKDL	4.000	

HLA-B7 (10-mer peptides)

1	50	YPGIEIESRL	80.000	
2	31	EPCGFEATYL	80.000	
3	18	EPGSGVRIVV	6.000	
example of improved peptide	EPGSGVRIVL	120.000	enhance P10	<u>SEQ ID NO:116</u>
4	106	TNSRPPCVIL	6.000	
5	80	NGGFPYEKDL	4.000	

Examples of predicted human Class I MHC binding peptides – continued

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

HLA-B8

1	107	NSRPPCVIL	4.000	
2	45	AVKEQYPGI	1.500	
3	105	ITNSRPPCV	0.600	
4	56	ESRLGGTGA	0.400	
5	100	ETLEKITNS	0.300	<i>S</i> is deleterious @ P9

example of improved peptide ETLEKITNL **12.000** **replace S with L @ P9** SEQ ID NO:117

HLA-B8 (8-mer peptides)

1	83	FPYEKDLI	6.000	
2	107	NSRPPCVI	1.000	
3	91	EAIRRASN	0.800	<i>N</i> is deleterious @ P8

example of improved peptide EAIRRASL **32.000** **replace N with L @ P9** SEQ ID NO:118

4	20	GSGVRIVV	0.600	
5	18	EPGSGVRI	0.400	

HLA-B8 (10-mer peptides)

1	50	YPGIEIESRL	0.800	
2	93	IRRASNGETL	0.400	

example of improved peptide IA RASNGETL **16.000** **replace R with A @ P2** SEQ ID NO:119

3	31	EPCGFEATYL	0.320	
4	104	KITNSRPPCV	0.300	
5	18	EPGSGVRIVV	0.240	

Examples of predicted human Class I MHC binding peptides – continued

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	----------------	-------------	--	------------

HLA-B*2702

1	57	SRLGGTGAF	200.000
---	----	-----------	---------

2	94	RRASNGETL	180.000
---	----	-----------	---------

example of
improved peptide

RRASNGETF	600.000
-----------	---------

enhance P9

SEQ ID NO:120

3	93	IRRASNGET	20.000
---	----	-----------	--------

4	27	VEYCEPCGF	15.000
---	----	-----------	--------

5	77	KLENGGFPY	9.000
---	----	-----------	-------

HLA-B*2702 (10-mer peptides)

1	93	IRRASNGETL	60.000
---	----	------------	--------

2	94	RRASNGETLE	6.000
---	----	------------	-------

3	30	CEPCGFPEATY	3.000
---	----	-------------	-------

4	58	RLGGTGAFEI	2.700
---	----	------------	-------

5	23	VRIVVEYCEP	2.000	P is deleterious @ P10
---	----	------------	-------	------------------------

example of
improved peptide

VRIVVEYCEY	200.000
------------	---------

replace P with Y @ P10

SEQ ID NO:121

HLA-B*2705

1	94	RRASNGETL	6000.000
---	----	-----------	----------

2	57	SRLGGTGAF	1000.000
---	----	-----------	----------

3	93	IRRASNGET	200.000
---	----	-----------	---------

example of
improved peptide

IRRASNGEL	2000.000
-----------	----------

enhance P9

SEQ ID NO:122

4	27	VEYCEPCGF	75.000
---	----	-----------	--------

5	77	KLENGGFPY	45.000
---	----	-----------	--------

Examples of predicted human Class I MHC binding peptides – continued

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

HLA-B*2705 (10-mer peptides)

1	93	IRRASNGETL	2000.000	
2	94	RRASNGETLE	60.000	<i>E</i> is deleterious @ P2

example of
improved peptide

RRASNGETLL 6000.000 replace E with L @ P2

SEQ ID NO:123

3	78	LENGGFPYEK	30.000
4	95	RASNGETLEK	30.000
5	58	RLGGTGAFEI	27.000

HLA-B*3501

1	31	EPCGFEATY	40.000
2	75	FSKLENGGF	22.500

example of
improved peptide

FPKLENGGM 120.000 enhance P2, P9

SEQ ID NO:124

3	107	NSRPPCVIL	15.000
4	42	LASAVKEQY	6.000
5	18	EPGSGVRIV	4.000

HLA-B*3501 (10-mer peptides)

1	31	EPCGFEATYL	30.000
2	50	YPGIEIESRL	20.000
3	56	ESRLGGTGAF	15.000
4	20	GSGVRIVVEY	10.000
5	83	FPYEKDLIEA	6.000

example of
improved peptide

FPYEKDLIEM 120.000 enhance P10

SEQ ID NO:125

Examples of predicted human Class I MHC binding peptides – **continued**

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)		SEQ ID NO.
------	-------------------	-------------	--	--	------------

HLA-B*3701

1	65	FEIEINGQL	15.000		
---	----	-----------	--------	--	--

example of
improved peptide

FDIEINGQL	60.000
-----------	--------

enhance P2

SEQ ID NO:126

2	47	KEQYPGIEI	10.000		
---	----	-----------	--------	--	--

3	85	YEKDLIEAI	10.000		
---	----	-----------	--------	--	--

4	17	VEPGSGVRI	10.000		
---	----	-----------	--------	--	--

5	35	FEATYLELA	5.000		
---	----	-----------	-------	--	--

HLA-B*3701 (10-mer peptides)

1	65	FEIEINGQLV	10.000		
---	----	------------	--------	--	--

example of
improved peptide

FDIEINGQLI	200.000
------------	---------

enhance P2, P10

SEQ ID NO:127

2	67	IEINGQLVFS	5.000		
---	----	------------	-------	--	--

3	81	GGFPYEKDLI	5.000		
---	----	------------	-------	--	--

4	87	KDLIEAIRRA	4.000		
---	----	------------	-------	--	--

5	30	CEPCGFPEATY	2.000		
---	----	-------------	-------	--	--

HLA-B*3801

1	34	GFEATYLEL	6.000		
---	----	-----------	-------	--	--

example of
improved peptide

GHEATYLEL	90.000
-----------	--------

enhance P2

SEQ ID NO:128

2	70	NGQLVFSKL	1.560		
---	----	-----------	-------	--	--

3	38	TYLELASAV	1.040		
---	----	-----------	-------	--	--

4	81	GGFPYEKDL	1.000		
---	----	-----------	-------	--	--

5	97	SNGETLEKI	0.720		
---	----	-----------	-------	--	--

Examples of predicted human Class I MHC binding peptides – **continued**

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

HLA-B*3801 (10-mer peptides)

1	64	AFEIEINGQL	7.800
---	----	------------	-------

example of
improved peptide

AHEIEINGQL 117.000

enhance P2

SEQ ID NO:129

2	31	EPCGFEATYL	4.800
---	----	------------	-------

3	66	EIEINGQLVF	3.000
---	----	------------	-------

4	26	VVEYCEPCGF	3.000
---	----	------------	-------

5	50	YPGIEIESRL	2.600
---	----	------------	-------

HLA-B*3901

1	94	RRASNGETL	15.000
---	----	-----------	--------

example of
improved peptide

RHASNGETL 90.000

enhance P2

SEQ ID NO:130

2	34	GFEATYLEL	9.000
---	----	-----------	-------

3	38	TYLELASAV	4.000
---	----	-----------	-------

4	66	EIEINGQLV	3.000
---	----	-----------	-------

5	2	SGEPGQTSV	3.000
---	---	-----------	-------

HLA-B*3901 (10-mer peptides)

1	33	CGFEATYLEL	12.000
---	----	------------	--------

example of
improved peptide

CHFEATYLEL 360.000

enhance P2

SEQ ID NO:131

2	64	AFEIEINGQL	9.000
---	----	------------	-------

3	93	IRRASNGETL	4.500
---	----	------------	-------

4	46	VKEQYPGIEI	3.000
---	----	------------	-------

5	16	EVEPGSGVRI	3.000
---	----	------------	-------

Examples of predicted human Class I MHC binding peptides – c ntinued

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

HLA-B*3902

1	70	NGQLVFSKL	2.400
---	----	-----------	-------

example of
improved peptide

NKQLVFSKL 24.000

enhance P2

SEQ ID NO:132

2	81	GGFPYEKDL	2.400
---	----	-----------	-------

3	94	RRASNGETL	2.000
---	----	-----------	-------

4	34	GFEATYLEL	2.000
---	----	-----------	-------

5	107	NSRPPCVIL	0.600
---	-----	-----------	-------

HLA-B*3902 (10-mer peptides)

1	69	INGQLVFSKL	2.400
---	----	------------	-------

2	64	AFEIEINGQL	2.400
---	----	------------	-------

3	50	YPGIEIESRL	2.400
---	----	------------	-------

4	80	NGGFPYEKDL	2.400
---	----	------------	-------

5	106	TNSRPPCVIL	2.000
---	-----	------------	-------

HLA-B*4403

1	67	IEINGQLVF	200.000
---	----	-----------	---------

example of
improved peptide

IEINGQLVY 900.000

enhance P9

SEQ ID NO:133

2	27	VEYCEPCGF	40.000
---	----	-----------	--------

3	21	SGVRIVVEY	36.000
---	----	-----------	--------

4	65	FEIEINGQL	20.000
---	----	-----------	--------

5	35	FEATYLELA	12.000
---	----	-----------	--------

Examples of predicted human Class I MHC binding peptides – continued

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

HLA-B*4403 (10-mer peptides)

1	30	CEPCGFEATY	120.000
---	----	------------	---------

2	53	IEIESRLGGT	30.000
---	----	------------	--------

example of
improved peptide

IEIESRLGGY	900.000
------------	---------

enhance P10

SEQ ID NO:134

3	67	IEINGQLVFS	30.000
---	----	------------	--------

4	65	FEIEINGQLV	20.000
---	----	------------	--------

5	17	VEPGSGVRIV	18.000
---	----	------------	--------

HLA-B*5101

1	18	EPGSGVRIV	484.000
---	----	-----------	---------

2	59	LGGTGAFEI	114.400
---	----	-----------	---------

example of
improved peptide

LPGTGAFEI	572.000
-----------	---------

enhance P2

SEQ ID NO:135

3	2	SGEPGQTSV	48.400
---	---	-----------	--------

4	81	GGFPYEKDL	44.000
---	----	-----------	--------

5	70	NGQLVFSKL	22.000
---	----	-----------	--------

HLA-B*5101 (10-mer peptides)

1	18	EPGSGVRIVV	440.000
---	----	------------	---------

2	44	SAVKEQYPGI	220.000
---	----	------------	---------

example of
improved peptide

SPVKEQYPGI	440.000
------------	---------

enhance P2

SEQ ID NO:136

3	31	EPCGFEATYL	220.000
---	----	------------	---------

4	81	GGFPYEKDLI	176.000
---	----	------------	---------

5	50	YPGIEIESRL	157.300
---	----	------------	---------

Examples of predicted human Class I MHC binding peptides – **continued**

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

HLA-B*5102

1	18	EPGSGVRIV	242.000
---	----	-----------	---------

2	81	GGFPYEKDL	110.000
---	----	-----------	---------

example of
improved peptide

GPFPYEKDI	2200.000	enhance P2, P9
-----------	-----------------	----------------

SEQ ID NO:137

3	59	LGGTGAFEI	96.800
---	----	-----------	--------

4	70	NGQLVFSKL	48.400
---	----	-----------	--------

5	2	SGEPGQTSV	24.200
---	---	-----------	--------

HLA-B*5102 (10-mer peptide)

1	44	SAVKEQYPGI	726.000
---	----	------------	---------

example of
improved peptide

SPVKEQYPGI	1452.000	enhance P2
------------	-----------------	------------

SEQ ID NO:138

2	50	YPGIEIESRL	400.000
---	----	------------	---------

3	81	GGFPYEKDLI	400.000
---	----	------------	---------

4	18	EPGSGVRIVV	220.000
---	----	------------	---------

5	31	EPCGFEATYL	121.000
---	----	------------	---------

HLA-B*5103

1	59	LGGTGAFEI	48.400
---	----	-----------	--------

example of
improved peptide

LAFTGAFEI	145.200	enhance P2
-----------	----------------	------------

SEQ ID NO:139

2	2	SGEPGQTSV	44.000
---	---	-----------	--------

3	18	EPGSGVRIV	44.000
---	----	-----------	--------

4	70	NGQLVFSKL	7.260
---	----	-----------	-------

5	81	GGFPYEKDL	7.200
---	----	-----------	-------

Examples of predicted human Class I MHC binding peptides – **continued**

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

HLA-B*5103 (10-mer peptide)

1	44	SAVKEQYPGI	110.000
2	81	GGFPYEKDLI	52.800
3	18	EPGSGVRIVV	44.000

example of
improved peptide

		EAGSGVRIVV	110.000	enhance P2
4	60	GGTGAFEIEI	44.000	
5	33	CGFEATYLEL	7.920	

SEQ ID NO:140

HLA-B*5201

1	18	WPGSGVRIV	75.000
2	67	LEINGQLVF	22.500

example of
improved peptide

		LQINGQLVI	450.000	enhance P2, P9
3	59	LGGTGAFEI	11.250	
4	98	NGETLEKIT	11.000	
5	19	PGSGVRIVV	10.000	

SEQ ID NO:141

HLA-B*5201 (10-mer peptides)

1	18	EPGSGVRIVV	100.000
2	17	VEPGSGVRIV	45.000

example of
improved peptide

		VQPGSGVRIV	450.000	enhance P2
3	81	GGFPYEKDLI	33.000	
4	105	ITNSRPPCVI	15.000	
5	37	ATYLELASAV	12.000	

SEQ ID NO:142

Examples of predicted human Class I MHC binding peptides – **continued**

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

HLA-B*5801

1	75	FSKLENGGF	40.000
---	----	-----------	--------

example of
improved peptide

FSKLENGGW	80.000
-----------	--------

enhance P9

SEQ ID NO:143

2	42	LASAVKEQY	4.500
---	----	-----------	-------

3	107	NSRPPCVIL	4.000
---	-----	-----------	-------

4	61	GTGAFEIEI	3.000
---	----	-----------	-------

5	105	ITNSRPPCV	3.000
---	-----	-----------	-------

HLA-B*5801 (10-mer peptides)

1	56	ESRLGGTGAF	12.000
---	----	------------	--------

2	20	GSGVRIVVEY	10.800
---	----	------------	--------

example of
improved peptide

GSGVRIVVEW	144.000
------------	---------

enhance P10

SEQ ID NO:144

3	1	MSGEPGQTSV	4.000
---	---	------------	-------

4	105	ITNSRPPCVI	3.000
---	-----	------------	-------

5	37	ATYLELASAV	3.000
---	----	------------	-------

HLA-Cw*0301

1	65	FEIEINGQL	30.000
---	----	-----------	--------

2	81	GGFPYEKDL	18.000
---	----	-----------	--------

3	70	NGQLVFSKL	12.000
---	----	-----------	--------

4	57	SRLGGTGAF	10.000
---	----	-----------	--------

5	34	GFEATYLEL	10.000
---	----	-----------	--------

Examples of predicted human Class I MHC binding peptides – **continued**

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

HLA-Cw*0301 (10-mer peptides)

1	44	SAVKEQYPGI	50.000
---	----	------------	--------

example of
improved peptide

SAVKEQYPGL 100.000

enhance P10

SEQ ID NO:145

2	33	CGFEATYLEL	45.000
---	----	------------	--------

3	69	INGQLVFSKL	12.000
---	----	------------	--------

4	81	GGFPYEKDLI	3.750
---	----	------------	-------

5	106	TNSRPPCVIL	3.000
---	-----	------------	-------

HLA-Cw*0401

1	34	GFEATYLEL	240.000
---	----	-----------	---------

2	38	TYLELASAV	30.000
---	----	-----------	--------

3	82	GFPYEKDLI	25.000
---	----	-----------	--------

4	18	EPGSGVRIV	20.000
---	----	-----------	--------

5	31	EPCGFEATY	12.000
---	----	-----------	--------

example of

improved peptide

EFCGFEATL 200.000

enhance P2, P9

SEQ ID NO:146

HLA-Cw*0401 (10-mer peptides)

1	64	AFEIEINGQL	200.000
---	----	------------	---------

2	74	VFSKLENGGF	100.000
---	----	------------	---------

example of

improved peptide

VFSKLENGGL 200.000

enhance P10

SEQ ID NO:147

3	50	YPGIEIESRL	80.000
---	----	------------	--------

4	31	EPCGFEATYL	80.000
---	----	------------	--------

5	18	EPGSGVRIVV	10.000
---	----	------------	--------

Examples of predicted human Class I MHC binding peptides – **continued**

Rank	Start Position	Subsequence	Score (estimated half time of dissociation)	SEQ ID NO.
------	-------------------	-------------	--	------------

HLA-Cw*0602

1	85	YEKDLIEAI	6.600	
2	65	FEIEINGQL	6.600	
3	21	SGVRIVVEY	6.000	
4	31	EPCGFEATY	3.300	
5	61	GTGAGEIEI	3.000	

HLA-Cw*0702

1	31	EPCGFEATY	24.000	
2	21	SGVRIVVEY	19.200	
3	42	LASAVKEQY	8.800	
4	77	KLENGGFPY	4.000	
5	49	QYPGIEIES	2.880	

HLA-Cw*0702 (10-mer peptides)

1	20	GSGVRIVVEY	38.400	
2	30	CEPCGFEATY	16.000	
3	41	ELASAVKEQY	16.000	
4	50	YPGIEIESRL	7.920	
5	76	SKLENGGFPY	4.000	